BillionToOne Launches Northstar Origin Liquid Biopsy Test
Menlo Park, California, USA, September 1, 2026 BillionToOne has launched Northstar Origin™, a new liquid biopsy add-on test designed...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Menlo Park, California, USA, September 1, 2026 BillionToOne has launched Northstar Origin™, a new liquid biopsy add-on test designed...
Princeton, New Jersey, USA, September 2, 2026 CytoSorbents Corporation has announced new real-world clinical data showing that use of...
DURHAM, N.C., July 27, 2026 Humacyte, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its...
